In transgenic and transplanted tumour models, the blockade of VEGF‐A and ANGPT2 by bispecific antibody (A2V) significantly enhances antitumour immunity and promotes the accumulation of CD8+ CTLs.194. This evidence concerns the gene VEGFA and neoplasm.